High-dose lymphoblastoid interferon in advanced XXXX : an Eastern Cooperative Oncology Group Study.

@entity1 @entity5 @entity409 @entity1358 @entity3027
This report describes a phase II Eastern Cooperative Oncology Group (ECOG) study of high-dose lymphoblastoid interferon ( @entity3027 -n1) in 39 @entity1 with measurable, advanced @entity1358 . The original treatment plan was 30 X 10(6) units/m2 (30 mU) of @entity3027 -n1 im daily X 10 days; treatments were repeated every 21 days. This dose and schedule proved intolerable, with none of seven @entity1 able to complete greater than 10 days of therapy because of fever, lassitude, @entity409 , and myelosuppression. @entity1 were subsequently treated with the following regimen: 3 mU/m2 on Day 1; 5 mU/m2 on Day 2; 10 mU/m2 on Day 3; and 20 mU/m2 on Days 4-10. Thirty-three new @entity1 received this regimen and two @entity1 received this schedule after having received 30 mU/m2. Using this second regimen, 30% of the @entity1 were able to complete two cycles of treatment without dose reduction or interruption. Five @entity1 (13%) had partial response (ECOG criteria) of measurable @entity5 . Median time to response was 140 days. Responses were documented in lung metastases in four @entity1 and in a pelvic soft tissue mass in the fifth. Response rates and survival times are similar to those seen in prior ECOG phase II trials in advanced @entity1358 . Eight of 39 @entity1 are still alive greater than 2 years after beginning therapy. Only two of these @entity1 had had an objective response, however. Such prolonged survival is more frequent than has been seen in previous ECOG studies. The relative contribution of @entity1 selection and interferon therapy to this survival is uncertain.
